IND/NDA Route To U.S. Herbals Market May Need Rethinking - U.S. Attorney
This article was originally published in The Tan Sheet
European marketers may want to reconsider the risks and costs of using the IND/NDA process to get herbals approved for marketing in the U.S., Washington, D.C. attorney Paul Hyman (Hyman, Phelps & McNamara) suggested at a recent IBC U.K. conference on herbals extract marketing in London.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC